The landscape of metastatic HER2-positive breast cancer is undergoing a seismic shift. For over a decade, the "CLEOPATRA" regimen—a combination of taxane chemotherapy with the monoclonal antibodies trastuzumab and pertuzumab—has served as the gold standard of care. However, the emergence of the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) has challenged this status quo, offering unprecedented efficacy in the first-line setting.
In a recent expert interview, Dr. Sara Tolaney, Chief of the Division of Breast Oncology at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School, discussed the transformative results of the DESTINY-Breast09 trial. The study’s findings, which have already garnered FDA approval in the United States, suggest that the era of aggressive, chemotherapy-heavy first-line regimens may be evolving toward a more targeted, potent future.
Main Facts: The New Benchmark in Metastatic Treatment
The DESTINY-Breast09 trial was designed with a singular, ambitious objective: to determine if T-DXd, either as a monotherapy or in combination with pertuzumab, could outperform the long-standing CLEOPATRA standard.
The trial’s interim analysis provided a decisive result. Patients treated with the doublet of T-DXd and pertuzumab experienced a near-doubling of progression-free survival (PFS) compared to those receiving the traditional CLEOPATRA regimen. This remarkable increase in the duration of disease control has led to a shift in clinical practice, with the FDA granting approval for the T-DXd and pertuzumab combination as a primary treatment option.
While the monotherapy arm of T-DXd did not meet its predefined success criteria at the time of the interim analysis, the clinical community has largely focused on the doublet’s success. For oncologists, this creates a new, high-performance baseline that balances the potent cytotoxic delivery of the ADC with the targeted blockade of the HER2 pathway.
Chronology of Clinical Development
To understand the weight of these findings, one must look at the historical trajectory of HER2-positive treatment:
- The CLEOPATRA Era: Established through the landmark CLEOPATRA trial, the combination of docetaxel, trastuzumab, and pertuzumab became the definitive first-line standard, significantly extending both PFS and overall survival (OS).
- The Rise of ADCs: The development of trastuzumab deruxtecan (T-DXd) revolutionized later-line settings, showing deep, durable responses in heavily pretreated patients.
- The DESTINY-Breast09 Pivot: Investigators initiated this trial to move T-DXd earlier in the treatment sequence. Last year’s interim data release confirmed the superiority of the T-DXd plus pertuzumab combination, signaling a major departure from the taxane-based foundation that has defined the last decade.
- Current Status: With FDA approval secured, the focus has shifted toward global regulatory approval and the refinement of patient selection criteria in the real-world setting.
Supporting Data and Clinical Efficacy
The core argument for adopting T-DXd plus pertuzumab lies in the magnitude of the PFS benefit. In oncology, doubling the time a patient remains progression-free is a rare and profound achievement.
"Generally speaking, we do like to use our most effective therapy up front," Dr. Tolaney explains. The rationale is prophylactic in nature; by deploying the most potent agent immediately, clinicians aim to prevent the rapid clinical decline associated with disease progression. While the scientific community awaits mature overall survival (OS) data, the PFS results are highly predictive of a long-term survival advantage.
However, the field is not without complexity. As Dr. Tolaney notes, other maintenance strategies—such as the use of palbociclib with endocrine therapy (PATINA) or tucatinib with HP (HER2CLIMB-05)—have also shown benefit. This creates a "paradox of choice," where clinicians must weigh the immediate benefits of T-DXd against established, effective maintenance protocols.
Managing Toxicity: The Interstitial Lung Disease (ILD) Challenge
The transition to T-DXd as a first-line agent is not without risks. The most significant concern for oncologists is the incidence of interstitial lung disease (ILD), which occurs in approximately 10–12% of patients treated with T-DXd.
Managing this risk requires a paradigm shift in clinical monitoring. Dr. Tolaney outlines a rigorous framework for patient safety:
- Patient Education: Transparency is the first line of defense. Patients are educated from the outset about the risks and the necessity of reporting new respiratory symptoms, such as persistent cough or shortness of breath, immediately.
- Frequent Imaging: While standard restaging scans typically occur every 9–12 weeks, Dr. Tolaney recommends a more aggressive schedule of 6–9 weeks for patients on T-DXd. This allows for the early detection of asymptomatic (Grade 1) ILD.
- Proactive Intervention: By catching ILD at its earliest, asymptomatic stages, clinicians can pause treatment, allow the lungs to recover, and safely resume therapy, thereby minimizing the risk of severe or life-threatening complications.
Implications for Clinical Practice and Future Research
The integration of T-DXd into the first-line setting represents a fundamental change in philosophy. For years, the goal was to avoid "burning bridges" by saving potent ADCs for later lines. Today, the prevailing view is that maximizing efficacy at the outset is the most reliable way to achieve long-term survival.
The Question of Maintenance
One of the most pressing questions in the field is whether patients need to be maintained on cytotoxic therapy until the point of progression. Future trials are actively exploring "induction-maintenance" strategies, testing whether patients can start with T-DXd and then transition to a less intensive maintenance therapy without sacrificing the durable responses gained in the first line.
Addressing the Overall Survival Gap
While the PFS data from DESTINY-Breast09 is compelling, the oncology community is waiting for event-driven OS data. Because patients with HER2-positive disease now live for many years, confirming an OS benefit requires significant time. However, given the profound improvement in PFS, the expectation of a significant OS benefit remains high among clinical experts.
Looking Toward the Future: ESMO Breast Cancer 2026
The discourse at major meetings, such as the recent ESMO Breast Cancer 2026, highlights the rapid pace of innovation. Discussions around the PHERGain-2 trial—which demonstrated a 60% pathologic complete response rate with a chemotherapy-free preoperative approach—suggest that the future of HER2-positive breast cancer may involve increasingly personalized, de-escalated therapies for early-stage disease, while simultaneously deploying high-intensity ADCs for advanced stages.
Conclusion: A New Standard of Care
The DESTINY-Breast09 trial has undeniably set a new benchmark for the treatment of metastatic HER2-positive breast cancer. By doubling progression-free survival, the combination of T-DXd and pertuzumab has provided a robust, effective, and now approved option for frontline therapy.
For the practicing oncologist, the transition requires a commitment to vigilance—particularly regarding pulmonary health—and a willingness to adapt to evolving treatment algorithms. While questions regarding long-term maintenance and the precise role of sequencing remain, the path forward is clear: the integration of potent, targeted antibody-drug conjugates is the new standard, and the potential to further improve outcomes through ongoing research remains vast.
As the field continues to refine these strategies, the focus remains on the patient. Whether through the de-escalation of therapy in early-stage disease or the aggressive, targeted approach in the metastatic setting, the goal is to provide treatments that not only extend life but preserve the quality of that life.
About the Expert
Dr. Sara Tolaney is a leading voice in breast oncology, recognized for her instrumental work in tailoring therapies for HER2-positive disease, CDK 4/6 inhibitors, and antibody-drug conjugates. As a member of the National Cancer Institute Breast Cancer Steering Committee and a key figure at the Dana-Farber Cancer Institute, her research continues to shape the international standard of care. Her work, published in top-tier journals such as the New England Journal of Medicine and the Journal of Clinical Oncology, serves as a cornerstone for modern breast cancer treatment protocols.
Disclaimer: The opinions expressed in this report are those of the featured expert and do not necessarily reflect the views of Oncology Central or the Taylor & Francis Group. Clinical decisions should always be based on the latest evidence-based guidelines and individual patient profiles.
About the Author
